Skip to content

A Clinical Trial Protocol of Life Enhancer Probiotic Capsules for Delaying Recurrent Urinary Tract Infections After Treatment in Middle-aged Women

A Clinical Trial Protocol of Life Enhancer Probiotic Capsules for Delaying Recurrent Urinary Tract Infections After Treatment in Middle-aged Women

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084080
Enrollment
Unknown
Registered
2024-05-10
Start date
2024-05-31
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Tract Infections

Interventions

Experimental group:Take Life Enhancer probiotics capsules orally, twice a day, one at a time
Control Group:Placebo, twice a day, one at a time

Sponsors

Shanghai Fourth People’s Hospital, School of Medicine, Tongji University, Shanghai, China.
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
35 Years to 100 Years

Inclusion criteria

Inclusion criteria: Meet diagnostic criteria for recurrent urinary tract infections: Diagnostic criteria for recurrent urinary tract infections: recurrent urinary tract infections in adults are defined as = 2 recurrent urinary tract infections in the past 6 months, or = 3 recurrent urinary tract infections in the past 12 months (2) Female= 35 years old (3) The onset of this disease met the diagnostic criteria for urinary tract infection, and the urine routine white blood cells were normal or the urine culture was negative after treatment (4) Sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Acute onset of urinary tract infection; (2) Urologic tract infections caused by mycoplasma, chlamydia, fungi, parasites, etc.; (3) Secondary urinary tract infection caused by urinary stones, etc.; (4) Combined with diabetes, heart, liver, kidney, hematopoietic system, respiratory system and other diseases or serious diseases that affect their survival; (5) Co-ordinated immune system disease or immune-related therapy within 1 month before enrollment; (6) History of urinary system tumors such as bladder tumors, uterine cancer, cervical cancer, vaginal cancer or urethral cancer; (7) Those who have participated in drug clinical trials in the past 3 months, or are taking other related Chinese and Western drugs, such as those who have taken preventive antibiotics to treat urinary tract infection. (8) Pregnant and lactating women

Design outcomes

Primary

MeasureTime frame
Disease progression-free duration of recurrence;

Secondary

MeasureTime frame
High magnification of white blood cell count in urinalysis;urine culture;

Countries

China

Contacts

Public ContactTie Zhou; Yonglian Zhang

Shanghai Fourth People’s Hospital, School of Medicine, Tongji University, Shanghai, China.

wenzhoutie@163.com+86 139 1836 0523

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026